SCHEMBL20139428

SCHEMBL20139428

CCc1cc(OCc2ccccc2)c(Br)cc1C=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
RAB9A P51151 2/20 0.49
PTPN1 P18031 2/20 0.48
LMNA P02545 3/20 0.47
HPGD P15428 3/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
CDK4 P11802 1/20 0.46
CCNB1 P14635 1/20 0.46
CCND1 P24385 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
ERN1 O75460 2/20 0.45
USP2 O75604 1/20 0.44
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TLR9 Q9NR96 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1539204 0.87 SMN1; SMN2 (0.52) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL590803 0.86 SMN1; SMN2 (0.50) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL20139379 0.84 PTPN1 (0.61) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL3606914 0.83 SMN1; SMN2 (0.52) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL207723 0.83 SMN1; SMN2 (0.49) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL2171253 0.83 SMN1; SMN2 (0.49) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL20140076 0.82 SMN1; SMN2 (0.46) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL7078292 0.82 ERN1 (0.56) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL3603467 0.81 PTPN1 (0.50) SMN1; SMN2RAB9APTPN1LMNAHPGD
SCHEMBL5646555 0.80 SMN1; SMN2 (0.49) SMN1; SMN2RAB9APTPN1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 SMN1; SMN2 3695/4885RAB9A 2959/4885PTPN1 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.